Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02618031 · ClinicalTrials.gov registry record · Phase 1
The Capillary Index Score Trial
A Phase 1 study of Ischemic Stroke and Acute Stroke, sponsored by Firas Al-Ali.
- Completed
- Registry status
- Phase 1
- Development phase
- 57
- Enrollment target
- 6
- Study locations
NCT02618031: Completed Phase 1 study of Ischemic Stroke and Acute Stroke, sponsored by Firas Al-Ali.
NCT02618031 is a Phase 1 study of Ischemic Stroke and Acute Stroke that has completed, run by Firas Al-Ali. The registered enrollment target is 57 participants, below the 1,463-participant average among 66 other Ischemic Stroke trials with a reported enrollment target (96% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02618031, a Phase 1 study of Ischemic Stroke and Acute Stroke, has completed, sponsored by Firas Al-Ali.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 57 participants
- Enrollment target
- 6
- Study locations
Study Summary
This study seeks to investigate the capillary index score (CIS) to further improve patient selection of endovascular treatment (EVT) in acute ischemic stroke (AIS). The hypothesis or idea being tested: Patients with favorable CIS who are successfully revascularized with EVT can have successful outcomes with an extended time window for treatment.
Primary Outcome
The mRS Score ranges from 0-6 and describes the degree of disability or dependence after a stroke. The grades are no symptoms (0), no significant disability (1), slight disability (2), moderate disability (3), moderately severe disability (4), severe disability (5), and death (6).
Conditions Studied
Interventions
- PROCEDURE Endovascular Treatment (EVT)
Study Locations (6)
New York
- New York University Langone Medical Center - New York
- Rochester General Hospital - Rochester
Georgia
- WellStar Atlanta Medical System - Atlanta
North Carolina
- University of North Carolina Hospital - Chapel Hill
Ohio
- Akron General Medical Center - Akron
Vermont
- University of Vermont Medical Center - Burlington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2016-03-01 |
| Est. Completion | 2018-12-31 |
| Phase | Phase 1 |
What the finished NCT02618031 record still lists
NCT02618031 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 57 participants, a relatively small participant target, below the 1,463-participant average among 66 other Ischemic Stroke trials with a reported enrollment target (96% lower).
The record links to 3 conditions, with Ischemic Stroke appearing as the primary indexed condition, and to 1 intervention - of which Endovascular Treatment (EVT) is the first listed.
NCT02618031 lists 6 locations in 5 states (New York, Georgia, North Carolina).
Frequently Asked Questions
What is clinical trial NCT02618031 about?
NCT02618031 is a clinical study titled "The Capillary Index Score Trial". This study seeks to investigate the capillary index score (CIS) to further improve patient selection of endovascular treatment (EVT) in acute ischemic stroke (AIS). The hypothesis or idea being tested: Patients with favorable CIS who are successfully revascularized with EVT can have successful out...
What is the current status of trial NCT02618031?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 57 participants. The study started on 2016-03-01. Estimated completion is 2018-12-31.
What conditions does trial NCT02618031 study?
This clinical trial studies the following conditions: Ischemic Stroke, Acute Stroke, Brain Ischemia.
What interventions are being tested in trial NCT02618031?
The interventions under investigation include: Endovascular Treatment (EVT) (PROCEDURE).
Who is sponsoring clinical trial NCT02618031?
This trial is sponsored by Firas Al-Ali, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02618031 being conducted?
This trial has 6 study locations across Georgia, New York, North Carolina, Ohio, Vermont. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ischemic Stroke
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02618031's enrollment target sits among peer trials
57 42nd of 66 higher than 25 of 66 other Ischemic Stroke trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ischemic Stroke trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Verapamil for Neuroprotection in Stroke
RECRUITING · Phase 1
-
Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability
RECRUITING · Phase 1
-
A Safety and Tolerability Study of Neural Stem Cells (NR1) in Subjects With Chronic Ischemic Subcortical Stroke (ISS)
ACTIVE NOT RECRUITING · Phase 1
-
A Study of NCS-01 in Patients With Acute Ischemic Stroke
ACTIVE NOT RECRUITING · Phase 1
-
Functional Magnetic Resonance Imaging (fMRI) and Robot-Assisted Practice of Activities of Daily Living
COMPLETED · Phase 1
-
Safety/Feasibility of Autologous Mononuclear Bone Marrow Cells in Stroke Patients
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03521830 · 57 participants · Phase 2
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
- NCT03587701 · 57 participants · Phase 2
Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease
- NCT04104126 · 57 participants · NA
Blood Flow Restriction Therapy in Achilles Injury
- NCT04703842 · 57 participants · Phase 1
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI